Lung Cancer in Norway
- PMID: 40617667
- DOI: 10.1016/j.jtho.2025.03.046
Lung Cancer in Norway
Conflict of interest statement
Disclosure Dr. Brustugun reports receiving institutional fees from Bristol-Myers Squibb, Amgen, Merck Sharp & Dohme, AstraZeneca, Pfizer, and Roche, outside the current work. Dr. Grønberg reports receiving advisory board and speaker fees from Eli Lilly, Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Accord, Janssen, Gilead, and Pfizer, outside the current work; and institutional fees for investigator-initiated trials from AstraZeneca and Roche. Dr. Aanerud reports receiving advisory board and speaker fees from Bristol-Myers Squibb and AstraZeneca, outside the current work. The remaining authors declare no conflict of interest.
Publication types
LinkOut - more resources
Full Text Sources
